Unmixed Trastuzumab Emtansine Conjugate from Japan
Antibody-drug conjugate targeting HER2 in breast cancer, qualifies as immunological per notes. Bulk unmixed under HTS 3002.13.00.
Duty Rate — Japan → United States
15%
Rate breakdown
9903.04.6215%Patented pharmaceutical articles that are the product of Japan, of a European Union member country, of South Korea, of Switzerland, or of Liechtenstein as provided for in subdivisions (c) and (f) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
Import Tips
• Document conjugate stability; FDA hazardous material declaration; confirm antibody component dominance